Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Currency in USD	2025
Operating Income	-1.09 Billion
Income Before Tax	-1.08 Billion
Income Tax Expense	0.00
Net Income	-1.08 Billion
Eps	-1.44
Epsdiluted	-1.44
Weighted Average Shs Out	747.70 Million
Weighted Average Shs Out Dil	747.70 Million
Research And Development Expenses	N/A
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	146.00 Thousand
Interest Expense	0.00
Interest Income	N/A
Net Interest Income	0.00
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	N/A
Ebitda	-1.09 Billion
Source	edgar
Ebit	-1.08 Billion

Summit Therapeutics Inc. Annual Reports (10-K)